Form 4: Becton Dickinson Executive Adjusts Holdings

Shana Carol Neal, EVP and Chief People Officer at Becton Dickinson & Co., reported a transaction involving common stock, with adjustments related to tax withholdings and a business combination.

Summary

• Shana Carol Neal, Executive Vice President and Chief People Officer of Becton Dickinson & Co. (BDX), reported a transaction on April 6, 2026.
• The transaction involved 1,146 shares of common stock.
• These shares were withheld for the payment of withholding taxes related to the vesting of restricted stock units.
• Additionally, direct holdings were adjusted due to the combination of BD's Biosciences and Diagnostic Solutions businesses with Waters Corp., impacting the number of shares underlying previously reported restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine insider transactions related to compensation and standard adjustments due to corporate actions, rather than significant performance indicators or strategic shifts.

Positives

• The transaction reflects standard procedures for tax withholding upon vesting of equity awards, indicating normal compensation and equity management.
• Adjustments to holdings due to business combinations suggest ongoing strategic corporate actions and integration processes.

Negatives

• The withholding of shares for taxes represents a reduction in the reporting person's direct equity ownership, albeit for a necessary obligation.

Risks

• Potential for future tax liabilities related to equity compensation.
• Uncertainty in the integration and performance of the combined Biosciences and Diagnostic Solutions businesses with Waters Corp.

Future Outlook

No specific forward-looking statements or guidance were provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for corporate insiders and reflect standard compensation and equity management practices within the medical technology and diagnostics industry. The reported adjustments related to business combinations are common in a sector characterized by M&A activity.

Comparison to Industry Standards

• The reporting of tax withholdings for vested restricted stock units is a standard practice across the healthcare and life sciences industries, including companies like Abbott Laboratories, Thermo Fisher Scientific, and Danaher Corporation.
• Adjustments to equity holdings due to business combinations are also typical in the industry, reflecting strategic realignments and integrations seen in companies such as Medtronic and Stryker.

Stakeholder Impact

• Shareholders: The transaction itself does not directly impact share price but provides transparency on executive equity holdings.
• Employees: The filing relates to executive compensation and equity awards, which are part of the broader employee compensation structure.
• Management: Reflects standard executive compensation practices and corporate restructuring.

Next Steps

• Continued monitoring of insider transactions for further insights into executive compensation and equity management.
• Tracking the performance and integration of the combined Biosciences and Diagnostic Solutions businesses.

Key Dates

Keywords

Becton Dickinson, BDX, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Executive Compensation, Tax Withholding, Business Combination, Securities Ownership